Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Imiquimod, in Patients With Progressive and/or Refractory Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs KiroVAX 003 (Primary) ; Cyclophosphamide; Imiquimod
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kiromic
- 10 Oct 2019 Status changed from active, no longer recruiting to discontinued.
- 13 Aug 2019 Planned End Date changed from 31 Mar 2019 to 31 Mar 2020.
- 13 Aug 2019 Planned primary completion date changed from 31 Mar 2019 to 31 Mar 2020.